Evelo Biosciences, Inc. Overview
Pro stress-test →Evelo Biosciences is a clinical-stage biotechnology company developing orally delivered product candidates that act on the small intestinal axis (SINTAX), which plays a central role in governing the immune, metabolic, and neurological systems. The company's therapies are pharmaceutical preparations of single microbe strains designed to treat inflammatory diseases and cancer.
Strategic Profile
Pro stress-test →Founded in 2015, Evelo has established a therapeutics platform based on the human immuno-microbiome. The company holds a worldwide exclusive license to this technology from the University of Chicago. The platform targets an underserved therapeutic intersection of immunology and microbiology with potential for orally delivered, affordable therapies.
Competitive Landscape
Pro stress-test →Evelo competes in the microbiome therapeutics and oncology immunotherapy spaces against established and emerging biotech firms. Direct competitors include traditional immunotherapy developers and emerging microbiome platforms, though Evelo's oral monoclonal microbial approach represents a distinct modality. The competitive landscape includes large pharma pursuing immuno-oncology and smaller biotech firms focused on microbiome interventions.
Industry Context
Evelo Biosciences, Inc. operates in Microbiome therapeutics.
Key facts
Founded: 2015 · Headquarters: Cambridge, US · Employees: 19–66 (February 2026: ~19; other sources cite 33–66) · Revenue: $1.5M–$25.8M (data variance reflects accounting source differences) · Market cap: N/A